Literature DB >> 35984607

Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.

Susan P Buchbinder1,2,3,4, Aaron J Siegler5, Kenneth Coleman6, Eric Vittinghoff7, Gretchen Wilde5, Annie Lockard5, Hyman Scott6,8, Peter L Anderson9, Nicole Laborde10, Ariane van der Straten8,11, Richard H Christie12, Michelle Marlborough12, Albert Y Liu6,8.   

Abstract

Measurement of adherence to oral pre-exposure prophylaxis (PrEP) in real-time has been challenging. We developed DOT Diary, a smartphone application that combines automated directly observed therapy with a PrEP adherence visualization toolkit, and tested its ability to measure PrEP adherence and to increase adherence among a diverse cohort of young men who have sex with men (MSM). We enrolled 100 MSM in San Francisco and Atlanta and randomly assigned them 2:1 to DOT Diary versus standard of care. Concordance between DOT Diary measurement and drug levels in dried blood spots was substantial, with 91.0% and 85.3% concordance between DOT Diary and emtricitabine-triphosphate and tenofovir-diphosphate, respectively. There was no significant difference in the proportion of participants with detectable PrEP drug levels at 24 weeks between study arms. These results suggest DOT Diary is substantially better than self-reported measures of adherence, but additional interventions are needed to improve PrEP adherence over time.
© 2022. The Author(s).

Entities:  

Keywords:  Adherence; Artificial intelligence (AI); Directly observed therapy (DOT); Men who have sex with men (MSM); Pre-exposure prophylaxis (PrEP)

Year:  2022        PMID: 35984607     DOI: 10.1007/s10461-022-03805-3

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  70 in total

1.  Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.

Authors:  Elske Hoornenborg; Liza Coyer; Roel C A Achterbergh; Amy Matser; Maarten F Schim van der Loeff; Anders Boyd; Yvonne T H P van Duijnhoven; Sylvia Bruisten; Paul Oostvogel; Udi Davidovich; Arjan Hogewoning; Maria Prins; Henry J C de Vries
Journal:  Lancet HIV       Date:  2019-06-06       Impact factor: 12.767

2.  Preexposure Prophylaxis Initiation and Retention in Care Over 5 Years, 2012-2017: Are Quarterly Visits Too Much?

Authors:  Laura K Rusie; Carlos Orengo; Diane Burrell; Arthi Ramachandran; Magda Houlberg; Kristin Keglovitz; David Munar; John A Schneider
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

3.  Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men.

Authors:  Thomas H F Whitfield; Steven A John; H Jonathon Rendina; Christian Grov; Jeffrey T Parsons
Journal:  AIDS Behav       Date:  2018-11

4.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Authors:  Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

5.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Authors:  Jean-Michel Molina; Isabelle Charreau; Bruno Spire; Laurent Cotte; Julie Chas; Catherine Capitant; Cecile Tremblay; Daniela Rojas-Castro; Eric Cua; Armelle Pasquet; Camille Bernaud; Claire Pintado; Constance Delaugerre; Luis Sagaon-Teyssier; Soizic Le Mestre; Christian Chidiac; Gilles Pialoux; Diane Ponscarme; Julien Fonsart; David Thompson; Mark A Wainberg; Veronique Doré; Laurence Meyer
Journal:  Lancet HIV       Date:  2017-07-23       Impact factor: 12.767

6.  Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics.

Authors:  Hyman M Scott; Matthew Spinelli; Eric Vittinghoff; Alicia Morehead-Gee; Anne Hirozawa; Catherine James; Hali Hammer; Albert Liu; Monica Gandhi; Susan Buchbinder
Journal:  AIDS       Date:  2019-11-15       Impact factor: 4.177

7.  Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials.

Authors:  Renata Arrington-Sanders; Craig M Wilson; Suzanne E Perumean-Chaney; Amit Patki; Sybil Hosek
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

8.  No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.

Authors:  Jonathan E Volk; Julia L Marcus; Tony Phengrasamy; Derek Blechinger; Dong Phuong Nguyen; Stephen Follansbee; C Bradley Hare
Journal:  Clin Infect Dis       Date:  2015-09-01       Impact factor: 9.079

9.  Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities.

Authors:  Philip A Chan; Leandro Mena; Rupa Patel; Catherine E Oldenburg; Laura Beauchamps; Amaya G Perez-Brumer; Sharon Parker; Kenneth H Mayer; Matthew J Mimiaga; Amy Nunn
Journal:  J Int AIDS Soc       Date:  2016-06-13       Impact factor: 5.396

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.